SCHEMBL4337152

SCHEMBL4337152

Cc1nc2cc(C(O[SiH](C)C)C(C)(C)C)ccc2[nH]1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.36
POLB P06746 4/20 0.36
KDM4E B2RXH2 3/20 0.36
HPGD P15428 2/20 0.36
ALDH1A1 P00352 3/20 0.36
GAA P10253 2/20 0.35
HSD17B10 Q99714 1/20 0.35
RAB9A P51151 3/20 0.33
MEN1 O00255 2/20 0.33
NPC1 O15118 2/20 0.33
KMT2A Q03164 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HSP90AA1 P07900 1/20 0.33
ESR2 Q92731 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CHRNB2 P17787 1/20 0.31
CHRNA4 P43681 1/20 0.31
ROCK2 O75116 1/20 0.31
PKM P14618 1/20 0.31
GLA P06280 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2076431 0.74 SLC6A2 (0.40) MAPTGAARAB9ANPC1
SCHEMBL6888843 0.74 ALDH1A1 (0.44) MAPTPOLBKDM4EHPGDALDH1A1
SCHEMBL12109783 0.72 ALDH1A1 (0.40) MAPTPOLBKDM4EHPGDALDH1A1
SCHEMBL1607217 0.71 MEN1 (0.41) POLBKDM4EHPGDALDH1A1HSD17B10
SCHEMBL28413241 0.71 ALDH1A1 (0.42) MAPTPOLBKDM4EHPGDALDH1A1
SCHEMBL13062631 0.69 SCN10A (0.47) MAPTPOLBKDM4EHPGDALDH1A1
SCHEMBL3825216 0.68 CYP2A6 (0.36) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL4798408 0.68 MLKL (0.43) KDM4EHPGDALDH1A1RAB9AMEN1
SCHEMBL24630921 0.68 ADRB2 (0.48) KDM4EKMT2ASMN1; SMN2TDP1
SCHEMBL4393880 0.67 MAPT (0.50) MAPTPOLBKDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569688-B2 Propane-1, 3-dione derivative ASTELLAS PHARMA INC. (JP) 2009-08-04 US disclosed
EP-1300398-B1 PROPANE-1,3-DIONE DERIVATIVES ASTELLAS PHARMA INC (JP) 2006-04-05 EP disclosed
US-20050267110-A1 Propane-1, 3-dione derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. 2005-12-01 US disclosed
US-6960591-B2 Propane-1,3-dione derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20030191164-A1 Propane-1,3-dione derivatives ASTELLAS PHARMA INC. (JP) 2003-10-09 US disclosed
EP-1300398-A1 PROPANE-1,3-DIONE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191164-A1 Propane-1,3-dione derivatives GNRHR, GPER1, FSHR MAPT 2864/4885POLB 2132/4885KDM4E 2229/4885
US-20050267110-A1 Propane-1, 3-dione derivative GNRHR, GPER1, FSHR MAPT 3016/4885POLB 2186/4885KDM4E 2190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.